-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target

Benzinga·10/23/2026 09:58:15
Diffusion vocale
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.